CompletedInterventionalPhase 1Updated Feb 26, 2020
Compassionate Use of Dupilumab | NCT04776694 | Trialant
Approved for marketingExpanded AccessUpdated Sep 22, 2025
Compassionate Use of Dupilumab
ClinicalTrials.gov ID
NCT04776694
Lead Sponsor
Regeneron PharmaceuticalsINDUSTRY
Overall Status
Approved for marketing
Study Type
Expanded Access
Last Update Posted
Sep 22, 2025Actual
Brief Summary
Provide Compassionate Use of Dupilumab
Detailed Description
Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications. Availability will depend on location.